[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Feily A, Pazyar N, Rafeie E, Khazanee A, Namazi MR: An unusually large squamous cell carcinoma mass arising from the lower lip. Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct;19(3):43-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusually large squamous cell carcinoma mass arising from the lower lip.
  • Squamous cell carcinoma (SCC) of the lip is a relatively common malignancy of the head and neck region.
  • We report an 81-year-old, otherwise healthy woman presenting with a huge friable mass originating from her lower lip.
  • The lesion was diagnosed histopathologically as squamous cell carcinoma.
  • The patient was advised to undertake palliative treatment such as surgery or chemotherapy, but she refused any intervention.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Lip Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20976422.001).
  • [ISSN] 1581-2979
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovenia
  •  go-up   go-down


2. Liang XH, He YW, Tang YL, Wu JL, Cao XP, Xiao GZ, Mao ZY: Thermochemotherapy of lower lip squamous cell carcinoma without metastases: an experience of 31 cases. J Craniomaxillofac Surg; 2010 Jun;38(4):260-5
MedlinePlus Health Information. consumer health - Fever.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thermochemotherapy of lower lip squamous cell carcinoma without metastases: an experience of 31 cases.
  • INTRODUCTION: The aim of this study was to evaluate the efficacy, functional and aesthetic results, and safety of a novel treatment, thermochemotherapy, for lower lip squamous cell carcinoma (LLSCC) without metastases.
  • PATIENTS AND METHODS: A combination of local hyperthermia delivered by a 915MHz microwave heating system and the chemotherapy of pingyangmycin (bleomycin A(5) hydrochloride) (PYM) and methotrexate (MTX), was administered to 31 patients of LLSCC twice per week for a period of 4.5-7.5 weeks.
  • RESULTS: Clinical CR was observed in twenty-nine (93.55%) patients and PR in two (6.45%), the total response rate was 100%, while the adverse effects were extremely minimal and tolerable in all 31 patients including 6 elderly patients with a compromised general condition.
  • CONCLUSION: This clinical study suggests that thermochemotherapy may be a feasible treatment for primary LLSCC without cervical metastases, especially for patients with extensive lesions and a compromised general condition.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Fever. Lip Neoplasms / therapy. Neoadjuvant Therapy. Neoplasm Metastasis / prevention & control
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / prevention & control. Male. Middle Aged. Recovery of Function. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19665900.001).
  • [ISSN] 1878-4119
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


3. Nakanome A, Shiga K, Sagai S, Ogawa T, Kobayashi T: [A case report of cancer of the lip--complete response by a neo-adjuvant chemotherapy using a novel method of TS-1 administration]. Gan To Kagaku Ryoho; 2006 Mar;33(3):353-6
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of cancer of the lip--complete response by a neo-adjuvant chemotherapy using a novel method of TS-1 administration].
  • We experienced a 49-year-old man with cancer of the lower lip (squamous cell carcinoma, T1N2cM0).
  • We planned surgical treatment including bilateral neck dissection and started a new TS-1 administration method as a neo-adjuvant chemotherapy.
  • One course of this chemotherapy consisted of 3 weeks'administration including 5-day administration and 2-day termination following 1 week rest.
  • After the first course of chemotherapy, the primary tumor disappeared, and the neck lymph node metastases were markedly reduced.
  • Histopathological examination revealed that there was no cancer cell but hyalinization in the removed specimen of lymph node, suggesting that the effect of the chemotherapy was a pathologically complete response.
  • We concluded that our novel TS-1 administration method was extremely effective for head and neck squamous cell carcinomas with high potential and without any severe side effects.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Lip. Lymph Nodes / pathology. Neck Dissection. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Drug Administration Schedule. Drug Combinations. Humans. Lymphatic Metastasis. Male. Middle Aged. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531717.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


Advertisement
4. Kübler AC, de Carpentier J, Hopper C, Leonard AG, Putnam G: Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy. Int J Oral Maxillofac Surg; 2001 Dec;30(6):504-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy.
  • Carcinoma of the lip is a common cancer of the head and neck area; its incidence is approximately one-quarter that for oral cavity cancers.
  • It occurs most frequently on the lower lip of elderly males.
  • This non-randomized Phase II study aimed to estimate the complete response (CR) rate to Foscan-mediated photodynamic therapy (Foscan-PDT) in patients with primary cancer of the lip, duration of CR, and the tolerability and safety of Foscan-PDT.
  • Twenty-five patients with squamous cell carcinoma (SCC) of the lip (Tis, T1, T2/N0/M0) and Karnofsky status > or = 70 received 0.15 mg/kg Foscan intravenously, followed 4 days later by a single non-thermal illumination of the tumour (light dose 20 J/cm2, irradiance 100 mW/cm2, lambda=652 nm).
  • The most common adverse event was swelling and local pain at the treatment site.
  • One patient developed a single lymph node metastasis 7 months after therapy.
  • The functional results were excellent in all patients without any signs of limited mouth opening or impaired lip closure.
  • The cosmetic outcome was better than after surgical therapy.
  • Foscan-PDT is an effective treatment modality for small primary tumours of the lips.
  • It allows preservation of form and function and does not compromise future treatment options for recurrent, residual or second primary disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Lip Neoplasms / drug therapy. Mesoporphyrins / therapeutic use. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Female. Follow-Up Studies. Humans. Injections, Intravenous. Laser Therapy. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Photosensitivity Disorders / chemically induced. Prospective Studies. Radiation Dosage. Remission Induction. Safety. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11829232.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


5. Kovács AF, Ghahremani MT, Stefenelli U, Bitter K: Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results. J Chemother; 2003 Oct;15(5):495-502
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results.
  • Adjuvant chemotherapy has not yet been proven to have a survival benefit for patients with head and neck cancer.
  • Studies dealing with this topic have had several faults like mingling tumor localizations and treatment modalities.
  • To re-examine the role of postoperative chemotherapy in oral cavity cancer, a single-center study was conducted with the attempt to have higher homogeneity.
  • 122 patients with primary squamous cell carcinoma of the lip, the oral cavity and the oropharynx have been treated with 100 mg/m2 cisplatin bolus infusion and 120-h continuous infusion of 1000 mg/m2 5-fluorouracil following radical surgery; 99 patients completed all 3 cycles.
  • The disease-free and overall survival are reported and compared to a control group of 161 patients with cancer of the lip, the oral cavity and oropharynx treated only with surgery, and a treatment-dependent prognostic index.
  • After a median follow-up of 79 months (range 5-18 years), the current 5-year overall survival of the chemotherapy group was 67% and the 5-year disease-free survival was 57% while the respective data for the control group are 46% and 40%.
  • The chemotherapy group suffered from fewer local and more neck relapses and had a much longer relapse latency (29 months versus 8 months).
  • The toxicity of the chemotherapy regimen was tolerable.
  • In a homogeneous population with resectable oral cavity and oropharyngeal cancer, postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil resulted in a high overall survival rate which was significantly better than in a comparable population treated only with surgery and better than the survival expectation calculated with the help of a prognostic index.
  • A prospective randomized study of postoperative chemotherapy versus control, exclusively in patients with oral cancer, is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Lip Neoplasms / drug therapy. Lip Neoplasms / surgery. Mouth Neoplasms / drug therapy. Mouth Neoplasms / surgery. Neoplasm Recurrence, Local. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14598943.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Wu CF, Chen CM, Chen CH, Shieh TY, Sheen MC: Continuous intraarterial infusion chemotherapy for early lip cancer. Oral Oncol; 2007 Sep;43(8):825-30
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous intraarterial infusion chemotherapy for early lip cancer.
  • Most lip cancers are usually diagnosed and can be treated with good prognosis at an early stage.
  • This study reports our experience of treating seven, previously untreated, patients with lip cancer in stage I or II using intraarterial infusion chemotherapy with a single agent.
  • In every case the tumor regressed dramatically and disappeared completely after treatment within a mean period of 2.5 months.
  • Only one patient died, of non-disease related pneumonia 3 years after infusion therapy.
  • The remaining patients are still alive and no recurrence of carcinoma has been observed at a median follow-up period of 28 months.
  • The side effects of infusion chemotherapy were mild and tolerable.
  • Our technique of continuous intraarterial infusion therapy for treatment of early lip cancers seems to be as effective as other standard techniques such as surgery or radiation therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Lip Neoplasms / drug therapy. Methotrexate / administration & dosage
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Follow-Up Studies. Humans. Infusion Pumps, Implantable. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207655.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Ng W, Jacob S, Delaney G, Barton M: Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care. Eur J Cancer; 2009 Aug;45(12):2150-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care.
  • BACKGROUND: We estimated the optimal chemotherapy utilisation rate for head and neck cancer as a benchmark for measuring and improving the quality of cancer care.
  • METHODS: An optimal chemotherapy utilisation tree was constructed using indications for chemotherapy that were identified from evidence-based treatment guidelines.
  • Data on the proportion of patient and tumour-related attributes for which chemotherapy was indicated were obtained and merged with the treatment indications to calculate the optimal utilisation rate.
  • The optimal chemotherapy utilisation rate was compared with actual utilisation rates reported.
  • RESULTS: Chemotherapy is indicated at least once in 36% (95% CI, 33-38%) of all patients with head and neck carcinoma.
  • The optimal utilisation rates by subsites were as follows: lip, 8%; oral cavity, 40%; nasopharynx, 69%; oropharynx, 66%; hypopharynx, 74%; larynx, 43%; salivary gland, 48% and paranasal sinus with nasal cavity, 38%.
  • CONCLUSIONS: The optimal proportion of patients who should receive chemotherapy in the head and neck carcinoma population has risen significantly over the past 20 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19285857.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


8. Gloster HM Jr: The use of second-intention healing for partial-thickness Mohs defects involving the vermilion and/or mucosal surfaces of the lip. J Am Acad Dermatol; 2002 Dec;47(6):893-7
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of second-intention healing for partial-thickness Mohs defects involving the vermilion and/or mucosal surfaces of the lip.
  • BACKGROUND: Partial-thickness defects involving the vermilion and mucosa of the lip are difficult to repair surgically.
  • OBJECTIVE: The purpose of this study was to evaluate the cosmetic and functional effectiveness of second-intention healing in the repair of partial-thickness defects confined predominantly to the vermilion and mucosa of the lip.
  • METHODS: Thirteen patients with squamous cell carcinoma of the lip underwent Mohs micrographic surgery, which resulted in partial-thickness defects predominantly confined to the vermilion and/or mucosa of the lip.
  • One patient whose defect extended to the cutaneous portion of the lip had deformation of the vermilion border.
  • CONCLUSIONS: Second-intention healing yields good to excellent cosmetic and functional results for the repair of partial-thickness defects involving the vermilion and/or mucosa of the lip.
  • Defects involving more than 2 mm of the cutaneous lip or defects extending deeper than the superficial portion of the orbicularis oris muscle may result in cosmetic or functional deformity or both if allowed to heal secondarily.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Dermatologic Agents / administration & dosage. Lip Neoplasms / surgery. Mohs Surgery / adverse effects. Postoperative Complications / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Esthetics. Female. Humans. Male. Middle Aged. Mouth Mucosa / pathology. Prognosis. Treatment Outcome. Wound Healing / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12451375.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents
  •  go-up   go-down


9. Kutluhan A, Kiriş M, Kaya Z, Kisli E, Yurttaş V, Içli M, Kösem M: Squamous cell carcinoma of the lower lip and supra-omohyoid neck dissection. Acta Chir Belg; 2003 Jun;103(3):304-8
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the lower lip and supra-omohyoid neck dissection.
  • PURPOSE: The aim of this study is to evaluate our approach to patients with squamous cell carcinoma of lower lip.
  • PATIENTS AND METHODS: This study includes 31 lower lip squamous cell carcinomas followed up between 1994 and 2000.
  • Primary treatment was applied to 28 patients of whom 23 were in stages I-II and five in stages III-IV.
  • Neck dissection was performed during primary lip resection in patients with palpable cervical lymph node involvement.
  • Patients with unpalpable cervical lymph nodes were divided into two subgroups: one was submitted to elective neck dissection (n = 11) and the other had isolated lip resection (n = 8).
  • Radiotherapy and chemotherapy were applied for curative and/or adjuvant treatment in addition to surgery in patients with locoregional recurrence and metastatic lymph nodes or with perineural involvement.
  • Delayed neck metastasis developed in one of the eight patients in whom isolated lip resection (without neck exploration) was performed.
  • COMMENT: Six patients (19%) died due to lower lip carcinoma in this series.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Lip Neoplasms / pathology. Lip Neoplasms / surgery. Lymph Node Excision
  • [MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12914368.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


10. Stanko P, Satko I, Czako L, Beno M, Danko J, Zmeko S: Squamous cell carcinoma of the oral cavity. Bratisl Lek Listy; 2007;108(7):292-6
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the oral cavity.
  • OBJECTIVES: A number of treatment modalities are available in the management of oral cavity cancer.
  • These are surgery (operation OP), irradiation (radiotherapy RT), chemotherapy (CHT), or complex therapy performed as a combination of the later three methods with various survival rates.
  • BACKGROUND AND METHODS: Authors analysed retrospectively a group of 622 patients (553 men, 69 women), mean age 58.6 years (range 23-88 years) hospitalised in the Department of Oral and Maxillofacial Surgery, Faculty Hospital and Faculty of Medicine Comenius University in Bratislava within the years 1992-2001 with primary untreated histologically confirmed squamous cell carcinoma of oral cavity (beside cancer of the lip and salivary glands).
  • Gender, age, location and TNM staging of the disease, clinical and histopathological evaluations of the neck lymph nodes and relationship to the treatment modalities were recorded.
  • RESULTS: The number of cases with squamous cell carcinoma of oral cavity increased by 37.31% in total as well as that of cases with advanced disease, especially stage IV (318 patients = 56.6%) increased by 7.6%.
  • Regarding the complexity of treatment, the best 5-year survival rates showed the complex three-modal therapy (CHT + OP + RT = 23.5%), comparing to the dual (OP + RT or CHT + RT = 19.4%) and mono-modal therapy (OP or RT alone = 17.2%).
  • In the complex therapy, the mean disease-free interval improved (30.2 vs 39.4 months) due to a change in the sequence of therapy modalities.
  • In spite of the fact that the overal 5-year survival was found not to improve, the quality of life regarding the mean disease-free interval in the group of patients under the complex treatment is considered to be a positive result (Tab. 3, Fig.
  • [MeSH-major] Carcinoma, Squamous Cell. Mouth Neoplasms


11. Saito N, Tsutsumida A, Saito A, Furukawa H, Suzuki K, Nishioka T, Yamamoto Y: [Squamous cell carcinoma of the lower lip, completely responding to concurrent chemoradiotherapy with S-1]. Gan To Kagaku Ryoho; 2008 Mar;35(3):495-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the lower lip, completely responding to concurrent chemoradiotherapy with S-1].
  • Concurrent chemoradiotherapy (CCRT) can be used in order to increase both the local and systemic control of head and neck carcinoma.
  • This report shows for the first time the assessment of CCRT with S-1 as a treatment modality for squamous cell carcinoma (SCC) of the lower lip.
  • Surgical excision is usually the first choice for the treatment of SCC of the lower lip, followed by reconstruction.
  • Such a treatment choice more or less compromises the cosmetic and/or functional status of the lip.
  • We present our experience of utilizing CCRT with S-1 as a mode of treatment for SCC of the lower lip that yielded significant results while preserving the integrity of the lip.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Lip Neoplasms / drug therapy. Lip Neoplasms / radiotherapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347403.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


12. Shapira MY, Abdul-Hai A, Resnick IB, Bitan M, Tsirigotis P, Aker M, Gesundheit B, Slavin S, Or R: Alefacept treatment for refractory chronic extensive GVHD. Bone Marrow Transplant; 2009 Feb;43(4):339-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alefacept treatment for refractory chronic extensive GVHD.
  • In this study, we describe the effect of alefacept treatment on chronic extensive GVHD (cGVHD).
  • The median time to initial response was 2.25 weeks and the response was marked (n=3), moderate (n=2) or minimal (n=4).
  • Complications that appeared during treatment included infection, pericarditis and squamous cell carcinoma of the lip.
  • All these events may be related to other drugs given simultaneously.
  • With a 30-month median follow-up, 6 of 12 patients are alive, with all but one with stable or improved cGVHD.
  • As reported earlier in psoriatic patients treated with alefacept, we found a consistent increase in the percentage of naive T cells as a consequence of treatment.
  • In conclusion, alefacept is effective for the treatment of cGVHD, and dose and time intervals of treatment should be explored further.
  • [MeSH-major] Graft vs Host Disease / drug therapy. Immunosuppressive Agents / therapeutic use. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child, Preschool. Chronic Disease. Cohort Studies. Female. Humans. Immunologic Memory / drug effects. Male. Middle Aged. Stem Cell Transplantation / adverse effects. T-Lymphocytes / drug effects. T-Lymphocytes / immunology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18850020.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Recombinant Fusion Proteins; ELK3V90G6C / alefacept
  •  go-up   go-down


13. Petruzzi M, De Benedittis M, Pastore L, Pannone G, Grassi FR, Serpico R: Isolated lichen planus of the lip. Int J Immunopathol Pharmacol; 2007 Jul-Sep;20(3):631-5
Hazardous Substances Data Bank. Clobetasol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated lichen planus of the lip.
  • Oral lichen planus (OLP) is a relatively common disorder whose cause is still unknown.
  • We report a case series of ten patients with a history of isolated swelling of the lower and/or upper lip, erosions and crusting.
  • Among the six different clinical variants of OLP described by Andreasen, the atrophic-erosive form was the most common in the course of isolated LP of the lip in our series.
  • A complete remission of lesions was observed in eight patients after topical treatment with clobetasol propionate 0.05 percent and tocopherol oil, while partial improvement was noted in those remaining.
  • Isolated LP of the lip is unusual and presents a diagnostic challenge; however an appropriate differential diagnosis is fundamental.
  • Isolated LP of the lip is a well-known condition which responds well to topical treatment with corticosteroids.
  • A thorough medical management and active early treatment are necessary to improve symptoms and might also be a relevant prevention strategy from squamous cell carcinoma risk, although data to fully support this statement still need investigation.
  • [MeSH-major] Lichen Planus, Oral / drug therapy. Lip / drug effects
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Clobetasol / administration & dosage. Clobetasol / therapeutic use. Cohort Studies. Drug Combinations. Female. Humans. Male. Middle Aged. Tocopherols / administration & dosage. Tocopherols / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17880776.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Drug Combinations; 1406-66-2 / Tocopherols; ADN79D536H / Clobetasol
  •  go-up   go-down


14. Cheshuk VE, Kravchenko AV, Lobanova OE, Medinets IuR, Maloed LG: [Local hyperthermia by means of ballon-type electrodes in combined therapy of patients with locally spread cancer of the mouth mucosa and lower lip]. Lik Sprava; 2004 Jan-Feb;(1):32-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local hyperthermia by means of ballon-type electrodes in combined therapy of patients with locally spread cancer of the mouth mucosa and lower lip].
  • Modification of the standard chemo- and radiotherapy with local hyperthermia gives evident positive results in treatment of patients with local cancer of tunica mucosa of mouth and lower lip.

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17051709.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


15. El Ghelbazouri N, Afifi Y, Benameur H, Bella A, Elhallaoui Y, Kettani F, Aït Ourhrouil M, Senouci K, Hassam B: [Oral verrucous carcinoma and human papillomavirus infection]. Ann Dermatol Venereol; 2007 Aug-Sep;134(8-9):659-62
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oral verrucous carcinoma and human papillomavirus infection].
  • [Transliterated title] Carcinome verruqueux buccal et infection à papillomavirus.
  • BACKGROUND: Verrucous carcinoma of the oral cavity is a clinical variant of squamous cell carcinoma.
  • PATIENTS AND METHODS: A 72 year-old woman with a history of actinic cheilitis consulted for a bulky tumour of the lips and palate.
  • Clinical examination revealed a highly infiltrated labial tumour vegetating and budding, with a thick edge.
  • Biopsy samples from both sites indicated well-differentiated veruccous epidermoid carcinoma with chorionic infiltration.
  • The patient died a few days before the start of preoperative chemotherapy following severe deterioration of her general state.
  • DISCUSSION: Verrucous carcinoma is an authentic well-differentiated low-grade cancer.
  • Diagnosis is based on histological examination.
  • Management and treatment are not codified but surgery remains the treatment of choice and relapse is common in the case of locoregional involvement.
  • [MeSH-major] Carcinoma, Verrucous / pathology. Human papillomavirus 16 / isolation & purification. Mouth Neoplasms / pathology. Papillomavirus Infections / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Female. Humans. Lip Neoplasms / pathology. Maxillary Diseases / pathology. Neoplasm Invasiveness. Nose Neoplasms / pathology. Osteolysis / pathology. Palatal Neoplasms / pathology. Palate, Hard / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925690.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Liang XH, Wang SZ, Mao ZY: [Effects of thermochemotherapy on immunologic function of patients with lip cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Mar;35(2):220-2
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of thermochemotherapy on immunologic function of patients with lip cancer].
  • OBJECTIVE: To evaluate the effects of thermochemotherapy on the immunologic function of lip cancer patients and to provide a theoretical basis for the clinical application of thermochemotherapy.
  • Each of the patients received the therapy twice a week for 5 weeks.
  • The lymphocyte transformation index after treatment was significantly higher than that before treatment (P < 0.01).
  • The CD4+ T cells and CD4+/CD8+ after treatment were significantly higher than those before treatment (P < 0.05); the CD8+ T cells after treatment was lower than that before treatment, but there was no statistically significant difference (P > 0.05).
  • CONCLUSION: Thermochemotherapy can enhance the lip cancer patient's T lymphocyte immunologic function, which possibly plays an important role in the treatment of lip cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / analogs & derivatives. Lip Neoplasms / drug therapy. Lip Neoplasms / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Aged. Aged, 80 and over. CD4-CD8 Ratio. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / immunology. Female. Hot Temperature. Humans. Lymphocyte Activation. Male. Methotrexate / administration & dosage. Microwaves. Middle Aged

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15071922.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 77108-50-0 / zhengguangmycin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


17. Yamamoto N, Hayashi Y, Kagami H, Fukui T, Fukuhara H, Tohnai I, Ueda M, Mizuno M, Yoshida J: Suicide gene therapy using adenovirus vector for human oral squamous carcinoma cell line in vitro. Nagoya J Med Sci; 2005 Jun;67(3-4):83-91
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suicide gene therapy using adenovirus vector for human oral squamous carcinoma cell line in vitro.
  • Recently, suicide gene therapy using the herpes simplex virus thymidine kinase (HSVtk) gene followed by ganciclovir (GCV) administration was evaluated for the treatment of cancer.
  • The purpose of this study was to investigate the effectiveness of suicide gene therapy using the replication-deficient recombinant adenovirus vector for human oral squamous carcinoma cell lines.
  • To evaluate transduction efficiency, each cell line was transduced in vitro with an adenovirus vector containing the beta-galactosidase gene.
  • Next, each cell line was transduced with an adenovirus vector containing the HSVtk gene, and a subsequent administration of GCV for the assessment of suicide gene therapy.
  • A subsequent administration of GCV resulted in complete tumor cell death.
  • In addition, we conducted a morphological analysis of that cell death using video-enhanced contrast differential interference contrast microscopy, and we observed that it included both apoptosis and necrosis after HSVtk gene and GCV treatment.
  • These results suggest that adenovirus-mediated suicide gene therapy induced remarkable cytotoxicity with a bystander effect in human oral squamous cell carcinoma thus suggesting an effective treatment strategy for that tumor.
  • [MeSH-minor] Antiviral Agents / pharmacology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / genetics. Dose-Response Relationship, Drug. Genetic Therapy / methods. Humans. Lip Neoplasms / genetics. Lip Neoplasms / pathology. Lip Neoplasms / therapy. Simplexvirus / enzymology. Transfection

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17375474.001).
  • [ISSN] 0027-7622
  • [Journal-full-title] Nagoya journal of medical science
  • [ISO-abbreviation] Nagoya J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiviral Agents; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


18. Yücel A, Cinar C, Aydin Y, Senyuva C, Güzel Z, Cetinkale O, Altintaŝ M: Malignant tumors requiring maxillectomy. J Craniofac Surg; 2000 Sep;11(5):418-29
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumors requiring maxillectomy.
  • Seventy cases with malignant tumors requiring maxillary resection in the past 10 years were reviewed, retrospectively.
  • The primary site of tumor was adjacent skin in 53%, maxillary sinus or maxilla in 20%, palate and alveolar arch in 13%, lip and buccal mucosa in 13%, and mandible in 1% of the cases.
  • The most common histopathological diagnoses was squamous cell carcinoma (54%), followed by basal cell carcinoma (20%).
  • Postoperative radiotherapy was performed in 32 patients and combined radiotherapy and chemotherapy in 12 patients.
  • Resection of the tumor with free surgical margins and appropriate evaluation of the surgical defect for the most suitable reconstruction are the mainstays of treatment of the midfacial tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Facial Neoplasms / surgery. Female. Humans. Lip Neoplasms / surgery. Male. Mandible / surgery. Mandibular Neoplasms / surgery. Maxillary Neoplasms / surgery. Maxillary Sinus Neoplasms / surgery. Middle Aged. Mouth Neoplasms / surgery. Neck Dissection. Neoplasm Recurrence, Local / surgery. Orbit Evisceration. Palatal Neoplasms / surgery. Palatal Obturators. Radiotherapy, Adjuvant. Retrospective Studies. Skin Neoplasms / surgery. Skin Transplantation / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11314064.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Scarisbrick JJ, Child F, Spittle M, Calonje E, Russell-Jones R: Systemic Hodgkin's lymphoma in a patient with Sézary syndrome. Br J Dermatol; 2000 Apr;142(4):771-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 71-year-old male with Sézary syndrome diagnosed in 1996 who subsequently developed systemic Hodgkin's lymphoma.
  • His only past treatment was bath psoralen plus ultraviolet A.
  • He has since been treated with multiagent chemotherapy (ChlVPP/PABLOE) which induced a remission in his Hodgkin's disease.
  • He has also developed a squamous cell carcinoma on the upper lip.
  • Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by a malignant proliferation of CD4-positive cells in the skin and peripheral circulation.
  • The CD4 count may be markedly elevated but this results from expansion of a neoplastic T-cell clone and there is a relative lymphopenia of normal T cells leading to a degree of immunoparesis.
  • Immunosuppression is known to be associated with an increased rate of malignancies and this may account for the occurrence of Hodgkin's disease and squamous cell carcinoma in this patient with Sézary syndrome.
  • [MeSH-major] Carcinoma, Squamous Cell. Hodgkin Disease. Lip Neoplasms. Neoplasms, Multiple Primary. Sezary Syndrome. Skin Neoplasms
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immune Tolerance / immunology. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Sezary syndrome.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10792230.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


20. Ryu S, Khan M, Yin FF, Concus A, Ajlouni M, Benninger MS, Kim JH: Image-guided radiosurgery of head and neck cancers. Otolaryngol Head Neck Surg; 2004 Jun;130(6):690-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients except one with cancer of the lip had received prior treatments including surgery, radiotherapy, and chemotherapy for the primary cancers.
  • The dose ranged 12 to 18 Gy for single-dose radiosurgery and 30 Gy in 5 or 6 fractions twice a week for fractionated radiosurgery.
  • Despite the recurrent disease from previous heavy treatments, 9 patients (70%) showed a significant response (complete or >50% tumor reduction) to radiosurgery, and 3 patients had stable disease.
  • The results indicate the potential of radiosurgery in the treatment of recurrent and selected primary head and neck cancers.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Radiosurgery / instrumentation. Surgery, Computer-Assisted / instrumentation
  • [MeSH-minor] Combined Modality Therapy. Dose Fractionation. Follow-Up Studies. Humans. Stereotaxic Techniques

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15195054.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Agra IM, Carvalho AL, Pontes E, Campos OD, Ulbrich FS, Magrin J, Kowalski LP: Postoperative complications after en bloc salvage surgery for head and neck cancer. Arch Otolaryngol Head Neck Surg; 2003 Dec;129(12):1317-21
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only patients with recurrent head and neck squamous cell carcinoma undergoing en bloc salvage resection were eligible for the study.
  • RESULTS: The tumor location was the lip in 6 patients, oral cavity in 55, oropharynx in 31, larynx in 24, and hypopharynx in 8.
  • Previous treatment was surgery alone in 20 patients, radiotherapy alone in 68, surgery and radiotherapy in 21, and radiotherapy and chemotherapy in 14.
  • An additional patient received chemotherapy alone before salvage surgery.
  • The occurrence of minor complications correlated with the previously treated site, with complications occurring more often in patients undergoing locoregional vs local treatment (P =.04).
  • Major complications were associated with the time between initial treatment and salvage surgery (P =.05).
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Salvage Therapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Length of Stay / statistics & numerical data. Logistic Models. Male. Middle Aged. Morbidity. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14676158.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Hodgson TA, Greenspan D, Greenspan JS: Oral lesions of HIV disease and HAART in industrialized countries. Adv Dent Res; 2006 Apr 01;19(1):57-62
HIV InSite. treatment guidelines - Non-ARV Adverse Events .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies from both the Americas and Europe report a decreased frequency of HIV-related oral manifestations of 10-50% following the introduction of HAART (highly active antiretroviral therapy).
  • The re-emergence of HIV-related oral disease may be indicative of failing therapy.
  • A possible association between an increased risk of oral squamous cell carcinoma and HIV infection has been suggested by at least three epidemiological studies, with reference to the lip and tongue.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / adverse effects. Carcinoma, Squamous Cell / complications. Developed Countries. HIV Infections / complications. Mouth Diseases / complications. Mouth Neoplasms / complications
  • [MeSH-minor] Candidiasis, Oral / complications. Candidiasis, Oral / drug therapy. Dental Care for Chronically Ill / psychology. Dental Caries / complications. Europe / epidemiology. Humans. Prevalence. Quality of Life. Salivary Gland Diseases / chemically induced. United States / epidemiology. Viral Load. Warts / chemically induced


23. Pollard JD, Hanasono MM, Mikulec AA, Le QT, Terris DJ: Head and neck cancer in cardiothoracic transplant recipients. Laryngoscope; 2000 Aug;110(8):1257-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Demographic data, risk factors, and disease course were evaluated in patients who developed cancer.
  • RESULTS: One hundred twenty patients (11.2%) developed 547 non-lymphomatous malignancies.
  • The average time from transplantation to development of cancer was 63.1 months.
  • Of cutaneous malignancies, 79.3% were squamous cell carcinoma and 15.9% were basal cell carcinoma Cutaneous malignancies most commonly presented on the scalp, cheek, lip, and neck.
  • Thirteen percent of cutaneous head and neck cancers behaved aggressively, requiring extensive management including radical surgery, radiation, and/or chemotherapy.
  • A total of 34.2% of cancer patients developed metastases and 54.9% of cancer patients died as a direct result of cancer.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Head and Neck Neoplasms / epidemiology. Heart Transplantation. Heart-Lung Transplantation. Lung Transplantation. Postoperative Complications. Skin Neoplasms / epidemiology


24. Mallia RJ, Subhash N, Sebastian P, Kumar R, Thomas SS, Mathews A, Madhavan J: In vivo temporal evolution of ALA-induced normalized fluorescence at different anatomical locations of oral cavity: application to improve cancer diagnostic contrast and potential. Photodiagnosis Photodyn Ther; 2010 Sep;7(3):162-75
MedlinePlus Health Information. consumer health - Mouth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The focal goal of this study is to identify optimal accumulation periods for ALA-induced PpIX in different healthy anatomical sites of human oral cavity and different types of abnormal mucosa to improve the accuracy of the clinical applications such as photodiagnosis and tissue grading.
  • MATERIALS AND METHODS: Laser-induced fluorescence (LIF) emission spectra, with excitation at 404 nm from a diode laser, were recorded with a miniature fiber-optics spectrometer from 13 anatomical sites of oral mucosa in 15 healthy volunteers and 30 suspicious sites in 15 patients after topical application of 0.4% 5-ALA solution for 15 min.
  • The optimal accumulation time in different anatomical sites of healthy subjects and abnormal tissues were determined by studying the temporal variation in normalized fluorescence intensities (NFI) at 635, 685 and 705 nm.
  • RESULTS AND DISCUSSIONS: In masticatory anatomical locations such as (gingival and hard palate) and in lining mucosa (inner lip, soft palate, floor of mouth, transition to floor of mouth, alveolus and ventral tongue) except vermillion border of lip (VBL) of healthy subjects (designated as group I), it was observed that optimum time for maximum accumulation of PpIX is 90 min.
  • In comparison, for lateral side of tongue (LST) and dorsal side of tongue (DST) tissues (designated as group II), maximum accumulation of PpIX was observed in 150 min of ALA application.
  • For diverse grade lesions of group I mucosa in patients, maximum accumulation of PpIX was observed in 90 min, whereas, in group II mucosa the optimum accumulation time was 150 min as in the case of healthy mucosa.
  • Further, between different grades oral mucosa, maximum variation in NFI take place at these optimal time periods.
  • CONCLUSIONS: The determination of the optimum accumulation time of ALA in oral mucosa based on NFI helps to improve the diagnostic contrast and accuracy of oral cancer diagnosis, and to plan appropriate timing for ensuing PDT.
  • [MeSH-major] Aminolevulinic Acid / pharmacokinetics. Mouth / metabolism. Mouth Diseases / diagnosis. Mouth Mucosa / anatomy & histology. Protoporphyrins / metabolism
  • [MeSH-minor] Administration, Topical. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Diagnosis, Oral. Humans. Mouth Neoplasms / diagnosis. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology. Photochemotherapy. Spectrometry, Fluorescence. Time Factors

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20728840.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


25. Kodama M, Watanabe D, Akita Y, Tamada Y, Matsumoto Y: Photodynamic therapy for the treatment of actinic cheilitis. Photodermatol Photoimmunol Photomed; 2007 Oct;23(5):209-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for the treatment of actinic cheilitis.
  • Although actinic cheilitis is a common disease, it should be treated carefully because it can undergo malignant transformation.
  • We report a case of actinic cheilitis treated with photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA), with satisfactory outcome in both clinical and pathological aspects.
  • Actinic cheilitis is a pathologic condition affecting mainly the lower lip caused by long-term exposure of the lips to the UV radiation in sunlight.
  • Analogous to actinic keratosis of the skin, actinic cheilitis is considered as a precancerous lesion and it may develop into squamous cell carcinoma.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Cheilitis / drug therapy. Photochemotherapy. Sunlight / adverse effects

  • Genetic Alliance. consumer health - Actinic Cheilitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17803601.001).
  • [ISSN] 0905-4383
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


26. Hauschild A, Lischner S, Lange-Asschenfeldt B, Egberts F: Treatment of actinic cheilitis using photodynamic therapy with methyl aminolevulinate: report of three cases. Dermatol Surg; 2005 Oct;31(10):1344-7, discussion 1348
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of actinic cheilitis using photodynamic therapy with methyl aminolevulinate: report of three cases.
  • BACKGROUND: Patients with actinic cheilitis should be treated to prevent transformation into invasive squamous cell carcinoma.
  • Treatment options comprise, for instance, destructive approaches, such as vermilionectomy and carbon dioxide laser ablation.
  • Photodynamic therapy (PDT) has demonstrated high efficacy in patients with epithelial skin cancers, but there is only one report on PDT with free delta-aminolevulinic acid (ALA) and noncoherent light in the treatment of actinic cheilitis.
  • OBJECTIVE: We report the treatment of three patients with actinic cheilitis with PDT using the new photosensitizing agent methyl aminolevulinate (methyl-5-amino-4-oxopenthanoate [MAOP]) combined with red light.
  • METHODS: MAOP was topically applied on the lower lip 3 hours before treatment with red light.
  • Two consecutive treatments, 1 week apart, were administered.
  • Clinical assessment was performed up to 13 months after the initial treatment.
  • Moderate to severe pain was associated with the application of the red light, and mild inflammation with edema of the lower lip occurred.
  • However, further studies are needed to compare the efficacy and cosmetic outcome with conventional treatment modalities.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Aminolevulinic Acid / analogs & derivatives. Cheilitis / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Sunlight / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Actinic Cheilitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16188193.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


27. Fields MT, Eisbruch A, Normolle D, Orfali A, Davis MA, Pu AT, Lawrence TS: Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys; 2000 Jun 1;47(3):785-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our Phase I clinical trial using once-weekly dFdCyd as a radiosensitizer in the treatment of patients with Stage IV squamous cell head and neck cancer has produced a high rate of tumor response and significant normal mucosal toxicity.
  • In vitro studies suggest that twice-weekly dFdCyd has the potential to be more effective than once-weekly dFdCyd when administered in combination with radiation (RT) given 5 days per week.
  • Therefore, we have used a mouse model to assess whether the therapeutic ratio of combined modality therapy may be improved by using a twice-weekly drug regimen.
  • 1) Does a once-weekly or twice-weekly dFdCyd regimen cause more normal tissue radiosensitization?
  • 2) Does a once-weekly or twice-weekly dFdCyd + RT regimen produce a better therapeutic index?
  • METHODS AND MATERIALS: To assess normal tissue toxicity, C3H mice underwent mouth (60)Co RT (27.5 Gy in 5 daily fractions) +/- dFdCyd delivered intraperitoneally (IP) either once or twice weekly 6 hours prior to irradiation.
  • Acute lip reactions were quantified according to a standard scoring system, and weight loss was measured.
  • We measured tumor control using squamous cell carcinoma (SCC) VII murine squamous cell flank tumors (50-125 mm(3)) treated with the same regimens used in the mouth irradiation model.
  • RESULTS: We found that dFdCyd delivered 800 mg/kg once weekly or 150 mg/kg twice weekly caused similar (and maximal tolerable) weight loss; therefore these regimens were chosen to test which schedule produced more acute lip radiosensitization.
  • Twice-weekly dFdCyd + RT was somewhat more toxic by weight loss (800 mg/kg once weekly: 11.9%; 150 mg/kg twice weekly: 17.7%; p = 0.09).
  • To assess therapeutic index, we treated SCC VII flank tumors with RT combined with isotoxic drug/RT regimens (dFdCyd 800 mg/kg once weekly or 100 mg/kg twice weekly).
  • Tumors treated with twice-weekly dFdCyd + RT were significantly smaller than tumors treated with once-weekly drug + RT at 28 days from the start of treatment (p < 0.03).
  • In addition, our findings suggest that for head and neck cancers twice-weekly dFdCyd may have a higher therapeutic index compared with once-weekly dFdCyd when combined with daily RT.

  • MedlinePlus Health Information. consumer health - Weight Control.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10837965.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078554; United States / NCI NIH HHS / CA / CA46592; United States / NCI NIH HHS / CA / R01 CA78554
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


28. Agra IM, Carvalho AL, Pinto CA, Martins EP, Filho JG, Soares FA, Kowalski LP: Biological markers and prognosis in recurrent oral cancer after salvage surgery. Arch Otolaryngol Head Neck Surg; 2008 Jul;134(7):743-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the prognostic effect of epidermal growth factor receptor (EGFR), matrix metalloproteinases 2 and 9, and vascular endothelial growth factor expression in patients with locally recurrent oral carcinoma after salvage surgery.
  • The previous treatment consisted of surgery in 33 patients (30.0%), radiotherapy with or without chemotherapy in 46 patients (41.0%), and surgery with adjuvant radiotherapy in 32 patients (29.0%).
  • The expression of EGFR, matrix metalloproteinases 2 and 9, and vascular endothelial growth factor was analyzed with a tissue microarray immunohistochemical technique.
  • In multivariate analysis, only the disease-free interval and the overexpression of EGFR were associated with a higher risk of cancer death.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Lip Neoplasms / pathology. Lip Neoplasms / surgery. Matrix Metalloproteinase 2 / analysis. Matrix Metalloproteinase 9 / analysis. Mouth Neoplasms / pathology. Mouth Neoplasms / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / surgery. Receptor, Epidermal Growth Factor / analysis. Salvage Therapy. Vascular Endothelial Growth Factor A / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Reoperation. Retrospective Studies

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18645125.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.24.24 / MMP2 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


29. Bhutto AM, Shaikh A, Nonaka S: Incidence of xeroderma pigmentosum in Larkana, Pakistan: a 7-year study. Br J Dermatol; 2005 Mar;152(3):545-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Xeroderma pigmentosum (XP) is a rare autosomal recessive inherited disorder caused by a defect in the normal repair of DNA of various cutaneous cell types damaged by exposure to ultraviolet radiation.
  • Twenty-nine patients developed ocular symptoms: photophobia, conjunctivitis, corneal keratitis and lid ulcer.
  • Histopathological findings revealed that six patients had squamous cell carcinoma (SCC) on the face, head, ear or lip.
  • The majority of cases (20/36, 55.6%) were from the Brohi tribe (skin type III), while the remaining cases (16/36, 44.4%) were from the Sindhi population (skin type IV).
  • The large number of XP patients seen in those with skin type III (Brohi tribe) compared with skin type IV (Sindhi population) indicates that the skin type and the race has a considerable value in the pathogenesis of XP.
  • Furthermore, 24 of 36 patients were in the severe group and six of these had SCC.
  • All patients were treated according to disease severity by prescribing oral antibiotics, local steroids, sunscreens and/or chemotherapy followed by irradiation in malignant cases.
  • Two patients died because of extensive SCC.

  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15787826.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Lin CY, Wang HM, Kang CJ, Lee LY, Huang SF, Fan KH, Chen EY, Chen IH, Liao CT, Chang JT: Primary tumor site as a predictor of treatment outcome for definitive radiotherapy of advanced-stage oral cavity cancers. Int J Radiat Oncol Biol Phys; 2010 Nov 15;78(4):1011-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tumor site as a predictor of treatment outcome for definitive radiotherapy of advanced-stage oral cavity cancers.
  • PURPOSE: To evaluate the outcome of definitive radiotherapy (RT) for oral cavity cancers and to assess prognostic factors.
  • METHODS AND MATERIALS: Definitive RT was performed on 115 patients with oral cavity cancers at Stages III, IVA, and IVB, with a distribution of 6%, 47%, and 47%, respectively.
  • The median dose of RT was 72 Gy (range, 62-76 Gy).
  • Cisplatin-based chemotherapy was administered to 95% of the patients.
  • Eleven patients underwent salvage surgery after RT failure.
  • RESULTS: Eight-eight (76.5%) patients responded partially and 23 (20%) completely; of the patients who responded, 18% and 57%, respectively, experienced a durable effect of treatment.
  • The 3-year PFS rates based on the primary tumor sites were as follows: Group I (buccal, mouth floor, and gum) 51%, Group II (retromolar and hard palate) 18%, and Group III (tongue and lip) 6% (p < 0.0001).
  • The T stage and RT technique did not affect survival.
  • CONCLUSION: The primary tumor site and neck stage are prognostic predictors in advanced-stage oral cancer patients who received radical RT.
  • The primary tumor extension and RT technique did not influence survival.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Cause of Death. Cisplatin / therapeutic use. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Radiation Injuries / pathology. Salvage Therapy / mortality. Survival Analysis. Taiwan. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20434273.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Agra IM, Carvalho AL, Ulbrich FS, de Campos OD, Martins EP, Magrin J, Kowalski LP: Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck; 2006 Feb;28(2):107-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Therapeutic decisions in recurrent oral and oropharyngeal squamous carcinoma (SCC) remain controversial.
  • METHODS: Two hundred forty-six consecutive patients who underwent salvage surgery for recurrent squamous cell carcinoma (SCC) of the oral cavity and oropharynx were studied.
  • The tumor sites were lip, 33 cases; oral cavity, 143; oropharynx, 70.
  • The previous treatment was surgery in 73 patients, radiotherapy in 96, combined surgery and radiotherapy in 76, and chemotherapy in one.
  • CONCLUSION: Patients with recurrent oral and oropharyngeal SCC at initial clinical stages (rCS I and II) and with a DFI greater than 1 year had a favorable prognosis.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Mouth Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Oropharyngeal Neoplasms / surgery. Salvage Therapy

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley Periodicals, Inc.
  • (PMID = 16388526.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Petruzzi M, De Benedittis M, Pastore L, Grassi FR, Serpico R: Peno-gingival lichen planus. J Periodontol; 2005 Dec;76(12):2293-8
Hazardous Substances Data Bank. Clobetasol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prevalence, treatment options, and management for this condition are far from being established, and research in this area primarily relies on anecdotes.
  • Following careful examination of the oral and genital mucosae, pathology was obtained, previous treatments and duration of mucosal lesions ascertained, treatment initiated, and response evaluated at 8 weeks on both oral and genital lesions.
  • The first-line drug was topical clobetasol propionate 0.05% cream in all cases; in case of failure, topical cyclosporin was used.
  • A review of the literature on treatment options for this rare condition was performed based upon standard literature review practices.
  • All patients responded to treatment except for one.
  • A thorough multidisciplinary medical management and active early treatment are necessary to improve symptoms and prevent genital sequelae and, given the risk of squamous cell carcinoma, as a preventative strategy, although this area still needs investigation.
  • Therapeutic trials relating to the treatment of peno-gingival lichen planus may be undertaken considering that current management relies exclusively on observations of case reports.
  • [MeSH-major] Lichen Planus / diagnosis. Lichen Planus, Oral / diagnosis. Penile Diseases / diagnosis
  • [MeSH-minor] Administration, Topical. Adult. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Candidiasis, Oral / etiology. Cheek / pathology. Clobetasol / administration & dosage. Clobetasol / analogs & derivatives. Clobetasol / therapeutic use. Cohort Studies. Follow-Up Studies. Gingival Diseases / diagnosis. Gingival Diseases / drug therapy. Glucocorticoids / administration & dosage. Glucocorticoids / therapeutic use. Humans. Lip Diseases / diagnosis. Lip Diseases / drug therapy. Male. Medical History Taking. Middle Aged. Remission Induction. Tongue Diseases / diagnosis. Tongue Diseases / drug therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Penis Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Periodontol. 2006 Feb;77(2):327
  • (PMID = 16332242.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Glucocorticoids; ADN79D536H / Clobetasol
  •  go-up   go-down


33. Stockfleth E, Sterry W, Carey-Yard M, Bichel J: Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol; 2007 Dec;157 Suppl 2:41-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head.
  • OBJECTIVE: In the USA, Imiquimod 5% cream is approved for use 2-3 times per week over 16 weeks for the treatment of actinic keratoses (AKs).
  • This study evaluated the efficacy of imiquimod in another treatment schedule, for AKs on the head.
  • PATIENTS: Patients were eligible if they had clinically typical, visible AK lesions located anywhere on the head, excluding the upper and lower eyelids, nostrils, lip vermilion, and inside the ears.
  • INTERVENTIONS: Patients applied study cream to the treatment area once daily 3x/week for 4 weeks (course 1) followed by a 4-week post-treatment period.
  • Patients with AK lesions remaining in the treatment area underwent a second 4-week treatment course.
  • MAIN OUTCOME MEASURES: Primary variable was the complete clearance rate, defined as the proportion of patients with no clinically visible AK lesions in the treatment area at the course 1 or course 2 post-treatment visit.
  • CONCLUSIONS: Shorter treatment regimen of imiquimod 5% cream can produce complete clearance rates similar to those seen with 16 weeks of treatment and has the advantage of lower drug exposure, resulting in a better benefit-risk profile for the patient.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Facial Neoplasms / drug therapy. Keratosis / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasms, Radiation-Induced / drug therapy. Neoplasms, Radiation-Induced / pathology. Patient Compliance. Treatment Outcome. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067631.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


34. Moore AS, Beam SL, Rassnick KM, Provost R: Long-term control of mucocutaneous squamous cell carcinoma and metastases in a horse using piroxicam. Equine Vet J; 2003 Nov;35(7):715-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term control of mucocutaneous squamous cell carcinoma and metastases in a horse using piroxicam.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Cyclooxygenase Inhibitors / therapeutic use. Horse Diseases / drug therapy. Lip Neoplasms / veterinary. Piroxicam / therapeutic use
  • [MeSH-minor] Animals. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Horses. Isoenzymes / antagonists & inhibitors. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local / veterinary. Prostaglandin-Endoperoxide Synthases. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14649366.001).
  • [ISSN] 0425-1644
  • [Journal-full-title] Equine veterinary journal
  • [ISO-abbreviation] Equine Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 13T4O6VMAM / Piroxicam; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


35. Asano Y, Ihn H, Shikada J, Kadono T, Kikuchi K, Tamaki K: A case of peplomycin-induced scleroderma. Br J Dermatol; 2004 Jun;150(6):1213-4
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Aged. Bleomycin / adverse effects. Carcinoma, Squamous Cell / drug therapy. Humans. Lip Neoplasms / drug therapy. Male

  • Genetic Alliance. consumer health - Scleroderma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15214916.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; 56H9L80NIZ / Peplomycin
  • [Number-of-references] 11
  •  go-up   go-down






Advertisement